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Induction of apoptosis has been demonstrated previously by overexpression of CD95 ligand (CD95L) in cultured
human melanoma cells. For in vivo approaches based on CD95L, however, targeted expression is a prerequisite
and tyrosinase promoters have been considered for selection. Luciferase reporter gene assays performed for a
representative panel of melanoma cell lines characterized by strong (SK-Mel-19), moderate (SK-Mel-13, MeWo),
weak (A-375), and missing expression (M-5) of endogenous tyrosinase revealed high tyrosinase promoter activities
in SK-Mel-19, SK-Mel-13, and MeWo, but only weak activities in A-375 and M-5 as well as in non-melanoma cell lines.
After transfection of a CMV promoter CD95L expression construct, melanoma cells were found highly sensitive, as
compared with non-melanoma cells. By applying a tyrosinase promoter CD95L construct, apoptosis was selec-
tively induced in SK-Mel-19, SK-Mel-13, MeWo as well as in A-375, which was characterized by high CD95 surface
expression and high sensitivity to agonistic CD95 activation. M5 and non-melanoma cell lines remained uninﬂu-
enced. Also, resistance to agonistic CD95 activation seen in MeWo characterized by weak CD95 surface expression
was overcome by overexpression of CD95L. Our investigations provide evidence that tyrosinase promoter CD95L
constructs may be of value for selective induction of apoptosis in therapeutic strategies for melanoma.
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Melanoma is a highly malignant tumor developing from
transformed melanocytes or nevus cells, and is character-
ized by increasing incidence within the last decades (Garbe
and Blum, 2001). Its clinical malignancy results from its
ability to form early metastasis as well as from its high re-
sistance to chemotherapeutic drugs (Serrone and Hersey,
1999). The cytotoxic activity of chemotherapeutic com-
pounds often coincides with the induction of apoptosis in
malignant cells. It seems that chemotherapy resistance is
related to defects in apoptotic signalling cascades and/or
increased expression of anti-apoptotic proteins (Radetzki
et al, 2002; Pommier et al, 2004) whereby apoptosis resist-
ance of tumor cells may be overcome by strong expression
of proapoptotic factors (Schulze-Bergkamen and Krammer,
2004).
CD95 ligand (CD95L/FasL) has been characterized as
a death ligand produced by immune cells for triggering
apoptosis in respective target cells (Krammer, 2000). It spe-
cifically binds on the cell surface and initiates formation of
the death inducing signalling complex that activates both
caspase cascades and mitochondrial cytochrome c release
in melanoma cells (Eberle et al, 2003).
In a previous study, we have shown that induced ex-
pression of CD95L in human melanoma cell lines activates
the CD95 signalling pathway and initiates apoptotic cell
death in vitro and in xenotransplants (Eberle et al, 2003).
Severe side-effects, however, such as liver toxicity have to
be taken into consideration by using this system in vivo, as
shown in mice treated systemically with agonistic CD95
antibodies (Ogasawara et al, 1993; Daniel et al, 2001).
Therefore, selective expression of CD95L seems to be a
necessary prerequisite when thinking of a CD95L-based
gene therapeutic approach for melanoma.
Specific cell targeting of transgene expression is pres-
ently attempted either by vector targeting (Nettelbeck et al,
2004) or by means of cell-specific promoters (Xie et al,
2001; Zhu et al, 2004). Pigment gene promoters as for the
pigmentation key enzyme tyrosinase (Sturm et al, 2001)
seem to be well suited for melanoma due to high and re-
stricted expression of pigment genes, and human or
murine-derived tyrosinase promoters have been used for
expression of suicide genes (Siders et al, 1998; Park et al,
1999; McCart et al, 2002; Rothfels et al, 2003) as well as for
targeting oncolytic adenoviruses to melanoma (McCart
et al, 2002; Nettelbeck et al, 2002).
The tyrosinase promoter constructs used generally con-
sist of a basal tyrosinase promoter element fused to one or
several copies of the distal tyrosinase enhancer that confers
high promoter activity due to internal M-box elements.
These contain binding sites for microphthalmia-associated
transcription factor (MITF), a basic-helix-loop-helix-type leu-
cine-zipper protein that contributes to specific activation of
Abbreviations: CD95L, CD95 ligand; MITF, microphthalmia-asso-
ciated transcription factor
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the tyrosinase promoter in pigment cells (Yasumoto et al,
1997).
In this study, we report specific induction of apoptosis in
human melanoma cells based on tyrosinase promoter-con-
trolled expression of CD95L whereby melanoma cells were
found highly sensitive to overexpression of CD95L, as com-
pared with other tumor cell lines. Apoptosis was induced
also in melanoma cells with only weak tyrosinase promoter
activity and resistance to agonistic CD95 activation was
overcome by CD95L expression. Thus, tissue-specific in-
duction of apoptosis by CD95L overexpression in combi-
nation with viral vectors may be considered for therapeutic
strategies in melanoma.
Results
Exogenous tyrosinase promoter activity is restricted to
pigmented melanoma cells Selective activity of the tyros-
inase promoter was investigated in three melanoma cell
lines with strong or moderate expression of endogenous
tyrosinase mRNA (SK-Mel-19, SK-Mel-13, and MeWo), in a
melanoma cell line with weak (A-375) and another without
any expression of endogenous tyrosinase mRNA (M-5). Ty-
rosinase mRNA levels of melanoma cell lines had been
determined previously (Eberle et al, 1995) and several non-
pigmented, non-melanoma cell lines (MCF-7, PFSK-1,
HeLa, and Hep-G2) were included in the study for compar-
ison.
Luciferase reporter gene assays performed after tran-
sient transfection of luciferase constructs driven by the
tyrosinase promoter, the CMV promoter or the SV40
promoter, respectively, showed significantly stronger activ-
ity of the CMV promoter as compared with the SV40 pro-
moter in all cell lines with the exception of SK-Mel-13. The
tyrosinase promoter was as strong or even stronger than
the CMV promoter in two pigmented melanoma cell lines
(SK-Mel-13 and SK-Mel-19) and it was at 6% of the CMV
promoter in another (MeWo). In contrast, the tyrosinase
promoter activity was only weak (less than 2% of the CMV
promoter) both in non-melanoma cell lines and in the me-
lanoma cell lines A-375 and M-5 characterized by weak or
missing expression of endogenous tyrosinase mRNA (Fig 1).
Thus, the tyrosinase promoter conferred selective expres-
sion of transgenes preferentially in melanoma cells with
strong or moderate expression of endogenous tyrosinase
mRNA.
Exogenous tyrosinase promoter activity in melanoma
cells corresponds to endogenous expression of tyros-
inase protein and of the transcription factor MITF For
further characterization of the cell lines used the expression
of endogenous tyrosinase as well as of the transcription
factor MITF reported to regulate tyrosinase promoter activ-
ity were studied by Western blot analysis. Significant tyros-
inase protein was detectable exclusively in SK-Mel-13,
SK-Mel-19, and in MeWo with the highest expression found
in SK-Mel-19 (Fig 2). These three cell lines were also pos-
itive for MITF expression. The two protein bands (60 and 55
kDa) detected for MITF had been reported to correspond to
phosphorylation at serine 73 (Hemesath et al, 1998) Non-
melanoma cell lines as well as melanoma cell lines A-375
and M-5 were negative for MITF expression indicating a
dominant role of MITF for the activities of both the genomic
Figure1
High tyrosinase promoter activity in melanoma cell lines charac-
terized by high expression of endogenous tyrosinase mRNA. Rel-
ative luciferase activities (arbitrary units) were determined 48 h after
transient transfection of melanoma cell lines SK-Mel-13, SK-Mel-19,
MeWo, A-375, and M-5 as well as of non-melanoma cell lines MCF-7,
PFSK-1, HeLa, and Hep-G2. Cells were transfected with luciferase re-
porter gene constructs under control of the SV40 promoter (white bars),
the CMV promoter (gray) and the tyrosinase promoter (black). Relative
luciferase activities were normalized by the median between the re-
spective SV40 and CMV values. The median was set individually for
each cell line to 100%. The complete experiment was performed three
times for the tyrosinase promoter and for the SV40 promoter and was
done twice for the CMV promoter, with each time triple values. Means
and standard deviations calculated from the data of all experiments are
presented here.
Figure2
Correlated expression of tyrosinase and microphthalmia-associ-
ated transcription factor (MITF) proteins. Expression of tyrosinase
and of MITF was determined by Western analysis for melanoma cell
lines SK-Mel-13, SK-Mel-19, MeWo, A-375, and M-5 as well as for non-
melanoma cell lines MCF-7, PFSK-1, HeLa, and Hep-G2. Expression of
the 70 kDa tyrosinase protein was restricted to the melanoma cell lines
SK-Mel-13, SK-Mel-19, and MeWo. In these three melanoma cell lines,
also MITF expression was detectable as two prominent protein bands
of 55 and 60 kDa, which were also seen in a normal human melanocyte
control culture (data not shown). Equal protein amounts (40 mg per lane)
were loaded and consistent blotting was confirmed by ponceau stain-
ing and by control analysis of b-actin. Western blot experiments were
performed twice using independent cell isolates giving highly similar
results.
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tyrosinase promoter and the transfected tyrosinase pro-
moter.
Melanoma and non-melanoma cell lines are sensitive for
agonistic CD95 activation To investigate any responsive-
ness for CD95-mediated apoptosis of the cell lines used, we
examined their CD95 surface expression and their sensitiv-
ity to CD95 activation by the agonistic antibody CH-11. By
using FACS analysis relatively high CD95 surface expres-
sion was seen in most cell lines examined, whereas weak
expression was found only in MCF-7 mammary carcinoma
cells and in MeWo (Fig 3).
Also, apoptosis was inducible in non-melanoma and in
most melanoma cell lines by CH-11 (Fig 4), whereby the
melanoma cell lines A-375 and SK-Mel-19 were found
highly sensitive and MeWo cells were largely resistant to
CH-11-induced apoptosis.
Selective induction of apoptosis in melanoma cells by
tyrosinase promoter-driven CD95L constructs To ad-
dress the question whether apoptosis can be selectively
induced in melanoma cells by cell type-specific expression
of CD95L, we constructed vectors containing CD95L cDNA
under control of a tyrosinase promoter (pTyr2-CD95L)
and the CMV promoter (pIRES-CD95L). Transfection with
pIRES-CD95L resulted in significant elevation of apoptosis
both in melanoma and in non-melanoma cell lines (Fig 5a).
In contrast, transfection of pTyr2-CD95L resulted in ef-
ficient induction of apoptosis exclusively in melanoma cells
(Fig 5b). Even higher apoptosis values as compared with the
CMV promoter construct were seen in melanoma cell lines
SK-Mel-13, SK-Mel-19, and MeWo. Interestingly, apoptosis
induction was also high in A-375 indicating that weak ty-
rosinase promoter activity can be overcome by the high
sensitivity of A-375 cells to CD95-dependent apoptosis. On
the other hand, no significant induction of apoptosis was
seen after transfection of pTyr2-CD95L in non-melanoma
cells and in M5 (Fig 5b). Cytotoxicity levels determined in
parallel as release of lactate dehydrogenase were increased
in the cell lines showing apoptotic responses (data not
shown).
To ascertain the relative number of dead cells in % after
CD95L transfection, trypan blue assays as well as bisbenzi-
mide nuclear stainings were performed for SK-Mel-13 and
A-375 after transfection with the tyrosinase promoter
CD95L construct and were compared with transfection
with the control plasmid. The relative numbers were deter-
mined with 25% and 31% for SK-Mel-13 and with 7.4% and
10% for A-375, whereas transfection with the control
plasmid resulted in less than 8% dead cells for SK-Mel-13
and less than 3% for A-375, respectively (Fig 6). Thus,
highly selective and strong induction of apoptosis was
shown to be achieved by tyrosinase promoter CD95L con-
structs in melanoma cells.
Figure 3
Melanoma and non-melanoma cell lines represent CD95 cell sur-
face expression. CD95 surface expression was determined by FACS
analysis in non-melanoma and melanoma cell lines. Cells were labelled
with a specific CD95 antibody (filled graphs) and with an isotypic con-
trol antibody (open graphs), respectively. A shift indicating relatively
high CD95 surface expression is seen in non-melanoma cell lines
PFSK-1, HeLa and Hep-G2 as well as in the melanoma cell lines SK-
Mel-13, A-375, SK-Mel-19, and M-5. Relatively weak CD95 surface
expression was seen in MeWo melanoma cells and in MCF-7 mammary
carcinoma cells. Western blot experiments were performed twice using
independent cell isolates giving highly similar results.
Figure4
Melanoma and non-melanoma cell lines are sensitive to CD95-
dependent apoptosis. Relative DNA fragmentation rates of melanoma
and non-melanoma cell lines treated for 16 h with a CD95 agonistic
antibody (CH-11) are shown (gray bars). For each cell line basic apo-
ptotic rates of untreated controls were individually set to 1 (white bars).
Clear induction of CD95-mediated apoptosis was seen in all cell lines
(po0.01, Student’s t test) with the exception of MeWo. The experiment
was performed twice with both times triple values. Means and standard
deviations of the values of both experiments are shown here.
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After transfection of pIRES-CD95L, apoptosis induction
was significantly stronger in most melanoma cell lines as
compared with non-melanoma cells. To rule out weaker re-
sponse of non-melanoma cells due to weaker transfection
efficiency or weaker expression of CD95L, the expression of
CD95L was monitored in two non-melanoma cell lines
(MCF-7 and PFSK-1) after transient transfection of pIRES-
CD95L and in SK-Mel-13, and no differences were found by
Western analysis (Fig 7a). Also, the levels of CD95L surface
expression were similar, as determined by FACS analysis
(Fig 7b).
Activation of apoptotic cascades after overexpression
of CD95L To investigate the signalling cascade after
transfection of CD95L constructs, caspase-8, caspase-3
and caspase-7 were monitored at the protein level in SK-
Mel-13 and A-375 cells. Overexpression of CD95L resulted
in the reduction of procaspases 3 and 8 (data not shown),
as well as in the formation of the 43/41 kDa caspase-8 in-
termediate fragments, the 18 kDa fragment of activated in-
itiator caspase-8 and the 19/17 kDa fragments of activated
main effector caspase-3. In addition, the 20 kDa fragment of
active effector caspase-7 was found in A-375 clearly indi-
cating activation of the caspase cascade after overexpres-
sion of CD95L (Fig 8). Since Bcl-2 proteins may play a
critical role in the regulation of apoptosis, the levels of anti-
apoptotic Bcl-2 and proapoptotic Bax were also investi-
gated. A-375 cells were characterized by a reduced Bcl-2 to
Figure 5
Selective induction of apoptosis in melanoma cells. Selective in-
duction of apoptosis as determined by relative DNA fragmentation
rates is shown in response to transient transfection of CD95 ligand
(CD95L) expression constructs. (a) Relative DNA fragmentation rates of
cell lines transiently transfected with a CMV promoter-CD95L construct
(pIRES-CD95L; filled bars) as compared with a control plasmid (pIRES;
open bars). Induction of apoptosis with the CMV promoter CD95L
construct was statistically significant in all cell lines as compared with
the control (po0.02, Student’s t test). (b) Relative DNA fragmentation
rates of cell lines transiently transfected with a tyrosinase promoter
CD95L construct (pTyr2-CD95L; filled bars) as compared with a control
plasmid (pTyrex-2; open bars). DNA fragmentation rates of cell lines
transfected with the respective control plasmid were set individually to
1. The experiments were performed three times for each construct with
each time triple values. Means and standard deviations of the values of
all three experiments are given here. Induction of apoptosis in SK-Mel-
13, SK-Mel-19, MeWo, and in A-375 with the tyrosinase promoter
CD95L construct was statistically significant (po0.01, Student’s t test).
Figure6
Determination of relative numbers of dead cells correlate with DNA
fragmentation assays. Relative numbers of dead cells in melanoma
cell lines SK-Mel-13 and in A-375 after transfection with the tyrosinase
promoter CD95 ligand construct (Tyr CD95L) or with the control plasmid
(Tyr C) were determined by typan blue staining (a) and by bisbenzimide
nuclear staining (b). The experiments were performed in triplicate. Sig-
nificant increase of dead and apoptotic cells, respectively, was found
after transfection with the tyrosinase promoter CD95L construct as
compared with the control (po0.02, Student’s t test). (c) Cell pictures
after bisbenzimide staining are shown, several positive cells are indi-
cated.
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Bax ratio as compared with SK-Mel-13 possibly meaningful
for the high sensitivity of these cells (Fig 8).
Discussion
Resistance to apoptotic stimuli contributes to disturbed
homeostasis in cancer leading to predominance of cell pro-
liferation versus cell death (Fulda and Debatin, 2003). Apo-
ptotic resistance may be overcome by overexpression of
proapoptotic genes, as shown previously for Bcl-XS and
CD95L in melanoma cells (Eberle et al, 2003; Hossini et al,
2003). For CD95-induced apoptosis, however, severe side
effects such as liver toxicity have been described in nude
mice treated systemically with agonistic anti-CD95 anti-
bodies to inhibit the growth of xenotransplants (Ogasawara
et al, 1993; Daniel et al, 2001). In consequence, cell type-
specific gene expression seems to be a necessary prereq-
uisite when thinking of anti-tumor approaches based on
overexpression of death ligands.
Tyrosinase is the key enzyme of melanin synthesis and its
expression is tightly restricted to melanocytic cells (Sturm
et al, 2001). In accordance with the previous data on the
activity of the tyrosinase promoter used (Park et al, 1999;
McCart et al, 2002) we found high activity of a tyrosinase
promoter reporter gene construct in melanoma cells after
transient transfection, whereas, its activity was neglectable
in non-melanoma cells. In addition, tight correlation of ex-
ogenous tyrosinase promoter activity with the endogenous
expression of tyrosinase in melanoma cells was seen; me-
lanoma cell lines characterized by high expression of en-
dogenous tyrosinase mRNA and of tyrosinase protein
showed high levels of activity, whereas other melanoma
cells were characterized by only weak tyrosinase promoter
activities.
With respect to the regulation of tyrosinase expression,
several isoforms of the transcription factor MITF have been
described as basic-helix-loop-helix-leucine-zipper proteins
(Saito et al, 2002) of which the M-isoform is expressed in
neural crest-derived melanocytes and binds to M-box ele-
ments in the tyrosinase promoter enhancer (Yasumoto et al,
1997). It plays an important role in melanocyte differentia-
tion (Goding, 2000) and may also drive high Bcl-2 expres-
sion required for survival of normal melanocytes (McGill
et al, 2002). Here, we found strong correlation of MITF and
tyrosinase protein expression in melanoma cell lines. This
may further indicate that exogenous tyrosinase promoter
Figure 7
CD95L is expressed equally well in melanoma and non-melanoma
cells after transient transfection. (a) Overexpression of CD95 ligand
(CD95L) protein in SK-Mel-13, MCF-7 and PFSK-1 is shown by West-
ern blot 48 h after transient transfection of pIRES-CD95L (CD95L).
Vector-transfected cells are shown as negative controls (C). As positive
control stably CD95L-transfected melanoma cells are shown (SKM13-
CD95L) in which CD95L is inducible by doxycycline (þD), versus non-
induced cells (D). Equal amounts of proteins were loaded (40 mg per
lane) and consistent blotting was confirmed by ponceau staining. For
each cell line double experiments from independent cultures have been
performed, giving highly similar results. (b) Surface expression of
CD95L is shown 48 h after transient transfection of pIRES-CD95L (filled
graphs) as determined by FACS analysis. Cells transiently transfected
with a control plasmid (pIRES) were used as negative controls (open
graphs). As a positive control, doxycycline-induced SKM13-CD95L
cells (filled graph) are shown versus non-induced SKM13-CD95L cells
(open graph). The overlay of the histograms of induced SKM13-CD95L
cells versus the control revealed a shift to higher fluorescence in in-
duced cells. This shift indicating CD95L surface expression is also seen
in the overlays of transiently transfected melanoma and non-melanoma
cells versus their respective controls.
Figure8
Caspase activation and protein levels of Bcl-2 and Bax. Western
blots for capase-8, caspase-3, caspase-7, Bcl-2, and Bax are shown
for melanoma cell lines SK-Mel-13 and A-375. Proteins were extracted
48 h after transient transfection of cells with either pTyr2-CD95L (Tyr
CD95 ligand (CD95L)), with pIRES-CD95L (CMV CD95L) or the re-
spective control plasmids without the CD95L cDNA (Tyr C; CMV C).
Identical protein amounts (25 mg per lane) were loaded in each lane,
consistent blotting was confirmed by ponceau staining and by detec-
tion of b-actin. Molecular weights of caspase cleavage products
(Casp), Bcl-2, Bax and b-actin are indicated on the right side. For each
cell line double experiments from independent cultures have been per-
formed, giving highly similar results.
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activity depends on MITF-M activity in target cells (Yasu-
moto et al, 1997; Vachtenheim and Drdova, 2004) being of
some importance for the applicability of these promoters in
melanoma therapies. Tyrosinase promoters may be ineffec-
tive in amelanotic melanomas with no MITF expression.
Selective targeting of toxic genes encoding Herpes sim-
plex virus thymidine kinase, Escherichia coli purine nucleo-
side phoshorylase or the diphteria toxin A chain to
melanoma cells by applying tyrosinase promoters has been
demonstrated in several studies (Siders et al, 1998; Park
et al, 1999; McCart et al, 2002; Rothfels et al, 2003). As
compared with toxic genes, the anti-tumor effect of proapo-
ptotic genes is supposed to produce a more physiological
response (Xie et al, 2001; Proskuryakov et al, 2003). In the
present investigation we found that the combination of the
CD95L with a tyrosinase promoter is able to selectively in-
duce apoptosis in human melanoma cells by activation of
the caspase cascade. On the other hand, when applying
a constitutive CMV control promoter, apoptosis was indu-
ced both in melanoma and in non-melanoma cell lines.
Transgenic CD95L expression was unequivocally verified at
the protein level and was also proven as surface expres-
sion. Using the tyrosinase promoter, the apoptotic response
in some pigmented melanoma cells was as high or even
higher compared with the CMV promoter, which is often
used for transgene expression due to its high activity (Xu
et al, 2002).
Although non-melanoma cells were clearly less sensitive
to CD95L plasmids, there was significant induction of
apoptosis in MCF-7, PFSK-1, and in HeLa cells after CMV
promoter-driven overexpression of CD95L. In general, how-
ever, melanoma cell lines revealed clearly higher sensitivity
to ectopic CD95L overexpression as demonstrated by CMV
promoter CD95L constructs, thus indicating the high po-
tential and effectiveness of ectopic CD95L overexpression
especially for melanoma cells. Furthermore, even weak ty-
rosinase promoter activities turned out to be sufficient for
inducing apoptosis by CD95L expression provided that the
cell line used was sensitive to CD95L. This has been dem-
onstrated for A-375 characterized by weak expression of
endogeneous tyrosinase mRNA shown previously (Eberle
et al, 1995) but low Bcl-2/Bax ratio (Raisova et al, 2001),
high CD95 surface expression, and highest susceptibility to
CD95-triggered apoptosis as shown here.
Apoptosis resistance may counteract death receptor-
based therapeutic approaches in tumor cells (Kamarajan
et al, 2003). Also, downregulation of death receptors was
shown to prevent signalling of death ligands in the TRAIL
system (Yang et al, 2003). In our experiments resistance of
melanoma cells was overcome by tyrosinase promoter-
driven overexpression of CD95L in the cell line MeWo,
which was found resistant to agonistic CD95 antibodies and
which is characterized by high Bcl-2/Bax ratio (Raisova
et al, 2001) and only weak CD95 surface expression, thus
demonstrating the high potential of ectopic overexpression
of death ligands.
In summary, our data provide evidence that combination
of CD95L with tyrosinase promoters is an effective strategy
for targeting of melanoma cells, due to selectivity of tyros-
inase promoters and high sensitivity of melanoma cells to
ectopic CD95L overexpression. As shown previously,
CD95L also can induce a bystander effect via its soluble
form and can sensitize melanoma cells for chemotherapeu-
tics (Eberle et al, 2003). Anti-tumor gene therapeutic ap-
proaches are still hampered by limitations in transduction
efficiencies in tumor cells (Heise and Kirn, 2000; Zhang et al,
2002). New vector systems such as replication-competent
adenoviruses may represent the urgently needed break-
through in this field (Zhang et al, 2002; Fechner et al, 2003;
Peter et al, 2003; Nettelbeck et al, 2004). Once efficient
vector systems are available, combined use of tyrosinase
promoters and CD95L appears as a suitable strategy
for apoptosis-based gene therapeutic approaches in
melanoma.
Materials and Methods
Cell culture Five human melanoma cell lines were used in the
present study: SK-Mel-13 (Carey et al, 1976), A-375 (Giard et al,
1973), SK-Mel-19 (Carey et al, 1976), MeWo (Bean et al, 1975), and
M-5 (Liao et al, 1975). SK-Mel-19 had been characterized previ-
ously by high endogenous expression of tyrosinase mRNA. SK-
Mel-13 and MeWo showed moderate tyrosinase mRNA expres-
sion, A-375 was characterized by only weak expression and M5
was completely negative for tyrosinase mRNA (Eberle et al, 1995).
In addition, the breast adenocarcinoma cell line MCF-7 (Soule et al,
1973), the neuroectodermal tumor cell line PFSK-1 (Fults et al,
1992) the cervical carcinoma cell line HeLa (Scherer et al, 1953),
and the hepatoma cell line Hep-G2 (Zannis et al, 1981) were ex-
amined. Cells were grown at 371C and 5% CO2. HeLa cells were
maintained in RPMI medium (Biochrom, Berlin, Germany), Hep-G2
cells were maintained in MEM medium (Biochrom), and all other
cell lines were maintained in DMEM (4.5 g per l glucose; Invitrogen,
Karlsruhe, Germany). All growth media were supplemented with
10% fetal calf serum and antibiotics (Biochrom).
The agonistic anti-CD95 antibody CH-11 (IgM mouse; Beckman
Coulter, Krefeld, Germany) was applied for 16 h in a concentration
of 0.25 mg per mL. As a positive control for CD95L expression,
stably transfected SKM13-CD95L cells were used, in which CD95L
is inducible by doxycycline (Eberle et al, 2003). The experiments
performed in this study have been approved by the Charite´-
Universita¨tsmedizin Berlin.
Plasmid constructs A CMV promoter CD95L construct (pIRES-
CD95L) resulted from subcloning of the full-length mouse CD95L
cDNA fragment (nucleotides 31–870, according to the sequence
described by Lynch et al, 1994) into the NotI and EcoRI sites of
pIRESneo (Promega, Mannheim, Germany). The tyrosinase pro-
moter used consisted of the basal element of the human tyrosinase
promoter and two upstream enhancer elements of the murine ty-
rosinase promoter (Park et al, 1999). A tyrosinase promoter CD95L
construct (pTyr2-CD95L) resulted from subcloning of the full-length
mouse CD95L fragment into BamHI and EcoRI sites of pTyrex-
PNP2 (Park et al, 1999) after the removal of the PNP gene. Lucif-
erase reporter gene assays were performed with pTyrex-2 (Park
et al, 1999) enclosing a tyrosinase promoter in front of the lucif-
erase gene, pGL3c enclosing a SV40 promoter in front of the
luciferase gene (Promega), and pAd5CMV-Luc enclosing a CMV
promoter in front of the luciferase gene. pAd5CMV-luc has been
constructed by insertion of a luciferase cDNA fragment into pZS2
(Fechner et al, 1999). Plasmid DNA for transfection experiments of
human cell lines was routinely isolated using the Endofree Plasmid
Maxi Kit (Quiagen, Hilden, Germany).
Transient transfection Human melanoma and non-melanoma
cells were seeded in six-well plates with 2  105 cells per well. For
transient transfection on the next day, cells at a confluence of 50%
were washed with serum-free Opti-MEM medium (Invitrogen)
followed by 4 h incubation at 371C with 1 mL per well of the
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respective transfection solution in Opti-MEM. Subsequently the
transfection solution was removed, and cells were incubated for
additional 44 h in their respective culture medium, before analysis.
In order to obtain comparable transfection efficiencies, the lipid
DMRIE-C (Invitrogen) and plasmid concentrations in the transfect-
ion solution had been adapted for each cell line according to lucif-
erase values obtained after transient transfection with pGL3c.
Volumes of DMRIE-C and amount of pGL3c plasmid used per 1 mL
transfection solution: 1 mL/0.02 mg (SK-Mel-13), 1 mL /0.2 mg (MCF-
7, PFSK-1), 1 mL /0.3 mg (A-375, M-5, HeLa), 2 mL /0.2 mg (Hep-G2),
2 mL/0.3 mg (MeWo), 4.2 mL /0.4 mg (SK-Mel-19). Other plasmids
were used in equimolar amounts.
Luciferase assay After transient transfection in six-well plates,
firefly luciferase activity was determined after 48 h using a lucif-
erase assay system (Promega). Wells were rinsed with phosphate-
buffered saline (PBS) and cells were scraped in 1 mL of reporter
lysis buffer. Cellular debris was then removed by centrifugation
(10,000  g), 2 mL of each lysate were mixed with 50 mL of lucif-
erase assay reagent buffer in eppendorf tubes, and light emission
was determined in a Liquid Scintillation Analyzer Tricarb 1600TR
(Canberra Packard, Frankfurt, Germany). Background emission
(reagent buffer) was subtracted, and relative luciferase activities
were calculated.
Quantiﬁcation of apoptosis and cytotoxicity Apoptosis was
quantified after transient transfection of CD95L constructs and
control plasmids after 48 h by using a cell death detection ELISA
(Roche Diagnostics, Mannheim, Germany), which detects mono-
and oligonucleosomes formed in apoptotic cells. In parallel to
apoptosis, relative cytotoxicity levels were determined by meas-
uring lactate dehydrogenase activity in the culture fluids using a
cytotoxicity detection system (Roche). For both assays the stand-
ard protocols of Roche have been applied. Relative apoptosis and
cytotoxicity rates after transfection of CD95L constructs were cal-
culated by normalization with the respective control plasmids
(pIRES and pTyrex-2, respectively). Statistical significance was
determined by Student’s t test.
For trypan blue staining of dead cells and bisbenzimide staining
of apoptotic nuclei, cells were harvested 48 h after transfection
by trypsin-EDTA treatment and were pooled with spontaneously
detached apoptotic cells collected before. After 1  washing with
PBS, a cell aliquot was mixed with an equal volume of trypan blue
solution (0.4% in 0.8 M NaCl; Sigma-Aldrich, Taufkirchen, Germa-
ny). A minimum of 500 cells were counted for each transfection
experiment performed in triplicate. Relative numbers of dead cells
were calculated as the percentage of blue cells to total cell counts.
Other cell aliquots were applied for cytospins (30,000 cells
each). For bisbenzimide staining, cytospins were fixed in 4% for-
maldehyde (methanol-free) for 30 min at 41C and washed 2  with
PBS. Cells were permeabilized by incubation for 5 min in a 0.2%
Triton X-100/PBS solution, washed 2  with PBS and stained
with Hoechst-33258 dye solution (1 mg per mL in PBS; Sigma) for
15 min at room temperature. After again washing 2  with PBS,
cells were mounted (MoBiTec, Go¨ttingen, Germany) and examined
by fluorescence microscopy. Apoptotic cells were identified by
condensed or by fragmented nuclei. For quantification, a minimum
of each 500 cells were counted for each transfection experi-
ment performed in triplicate. The ratio of apoptotic cells was cal-
culated as percentage of cells with condensed nuclei to total cell
counts.
CD95L and CD95 surface expression analyses For analysis of
CD95L surface expression, cells were transiently transfected with
CD95L expression plasmids and control plasmids, respectively,
and were harvested from culture plates by treatment with 0.02%
EDTA in PBS. After washing with PBS, aliquots of 1  106 cells in
100 mL PBS, 1% BSA were incubated with phycoerythrin-labelled
monoclonal CD95L antibody (clone MFL3; sc-19986PE, Santa
Cruz, Heidelberg, Germany), as recommended by the manufac-
turer. After washing with PBS, surface expression was determined
with a FACSCalibur flow cytometer (Becton Dickinson, Heidelberg,
Germany). The mean fluorescence index was calculated using
CellQuest software (Becton Dickinson).
CD95 surface expression was detected by FACS analysis of
untransfected cells incubated either with a phycoerythrin-labelled
monoclonal CD95 antibody (clone DX2; Becton Dickinson) as
compared with an isotypic labelled IgG1 monoclonal control an-
tibody (clone MOPC-21, Becton Dickinson).
Western blot analysis For protein extraction, cells at a conflu-
ence of 60%–80% were washed with PBS and then immediately
lysed in the respective lysis buffer. Lysis buffer for Bax, Bcl-2, MITF
and tyrosinase: 10 mM Tris-HCl, pH 7.5, 144 mM NaCl, 1% Non-
idet P-40, 0.5% sodium dodecyl sulfate (SDS), 1 mM EDTA, 2 mM
phenylmethylsulfonyl fluoride (PMSF), 10 mg per mL trasylol (Bayer,
Leverkusen, Germany), 20 mM leupeptin, and 10 mM pepstatin.
Lysis buffer for caspase analysis: 50 mM PIPES/HCl, pH6.5, 2 mM
EDTA, 0.1% Chaps, 40 mM leupeptin, 15 mM pepstatin, 10 mg per
mL trasylol, and 5 mM DTT (New England Biolabs, Frankfurt am
Main, Germany). Lysis buffer for CD95L: 50 mM Tris-HCl, pH 7.5,
2 mM EDTA, 400 mM PMSF, 8 mM leupeptin, 6 mM pepstatin, 0.1%
SDS, and 0.1% Triton X-100.
For Western blotting, cell lysates were homogenized and cen-
trifuged for 5 min at 10,000  g. Equal protein amounts were sep-
arated by electrophoresis under reducing conditions on 12% or
15% SDS-polyacrylamide gels in parallel with a broad range pre-
stained SDS-PAGE protein standard (BioRad, Mu¨nchen, Germany).
Transfer of proteins to blotting membranes, ponceau staining and
immunodetection of transferred proteins were performed as de-
scribed previously (Eberle et al, 2003).
The following antibodies have been used: CD95L (rabbit poly-
clonal IgG, N-20, sc-834, Santa Cruz, 1:250); caspase-3 (mouse
monoclonal IgG, 9661, New England Biolabs; 1:1000); caspase-8
(mouse monoclonal IgG, 9746, New England Biolabs; 1:1000);
caspase-7 (mouse monoclonal IgG, 9492, New England Biolabs;
1:1000); Bcl-2 (mouse monoclonal IgG, sc-509, Santa Cruz, 1:200);
Bax (rabbit polyclonal IgG, sc-493, Santa Cruz; 1:400); MITF
(mouse monoclonal IgG Ab-3, clone C5 and D5, Biocarta, Ham-
burg, Germany, 1:200); tyrosinase (mouse monoclonal IgG, clone
T311, Oncogene, San Diego, California, 1:1000); b-actin (mouse
monoclonal, clone AC-15, Sigma-Aldrich, 1:10000). Two second-
ary horseradish peroxidase-labelled antibodies were used (HRP-
labelled goat anti-rabbit immunoglobulins and HRP-labelled goat
anti-mouse immunoglobulins, both from DakoCytomation, Ham-
burg, Germany, 1:5000).
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